About us

Board of directors and management

Scientific and clinical advisory board

  • Prof Rob E. Coleman · Chairman

    Rob E. Coleman is the director of Cancer Clinical Trials Centre, the Academic Unit of Clinical Oncology at the University of Sheffield. He is the leader of the new CR-UK / YCR Sheffield Cancer Centre. From 2004 to 2009 he was chairman of the National Cancer Research Institute Breast Cancer Study Group in the UK and is also a past-president of the Cancer and Bone Society (2005-08).

  • Prof Dan F. Hayes

    Dan F. Hayes is currently president of ASCO and is the director of the breast oncology program at the University of Michigan Cancer Center, where he is also a professor of medicine. He co-chairs the expert panel for tumor marker practice guidelines for the American Society of Clinical Oncology, the Southwest Oncology Group and the U.S. Breast Cancer Intergroup.

  • Prof Giuseppe Viale

    Giuseppe Viale is the director of pathology and laboratory medicine at the IEO and professor of pathology at the University of Milan School of Medicine. He is an active member of many international societies, organizations and committees and is co-chairman of the central pathology office of the International Breast Cancer Study Group (IBCSG) and the scientific committee of the International Breast Cancer Study Group (IBCSG).

  • Prof Andrew Tutt

    Andrew Tutt is the director of the Breakthrough Breast Cancer Research Unit at Kings College, London. He is a professor of oncology at King’s College, London and consultant oncologist in the multidisciplinary breast unit at Guy’s and St Thomas’ NHS Foundation Trust. He is also a member of the St Gallen early breast cancer international guidelines consensus panel.

  • Prof Joan Albanell

    Joan Albanell is the head of the medical oncology department at Hospital del Mar in Barcelona. He is a founding member of GEICAM (Spanish Group of Breast Cancer Research), coordinator of the group transGEICAM and member of the board of directors of SEOM (Spanish Society of Medical Oncology)